Nesfatin-1 was discovered in 2006 as a novel anorexigenic peptide, generated from the cleavage of nucleobindin-2 (NUCB2). Its ability to reduce food intake independently of leptin makes it a particularly interesting target for obesity research, since leptin resistance is a hallmark of most human obesity.
Dosage Information (Research Use)
Research doses: 5-25 pmol ICV in rodent studies. No standardized human dosing. Peripheral administration less effective due to limited BBB penetration. Research compound only.
Reconstitution & Handling
Reconstitute in sterile saline or PBS.
Half-Life & Pharmacokinetics
~10-20 minutes (estimated)
Reported Observations in Literature
Reduced food intake (intended effect). May produce mild anxiety at higher doses. Limited human safety data available.
Key Research References
- Oh-I S et al. “Identification of nesfatin-1 as a satiety molecule in the hypothalamus.” Nature. 2006;443:709-12